Cantor Fitzgerald Has Weak Outlook for UTHR FY2025 Earnings

United Therapeutics Corporation (NASDAQ:UTHR) – Research analysts at Cantor Fitzgerald decreased their FY2025 EPS estimates for United Therapeutics in a research report issued on Thursday, July 31st. Cantor Fitzgerald analyst O. Brayer now expects that the biotechnology company will earn $28.43 per share for the year, down from their previous estimate of $28.53. Cantor Fitzgerald has a “Overweight” rating and a $405.00 price objective on the stock. The consensus estimate for United Therapeutics’ current full-year earnings is $24.48 per share.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%. The business had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. During the same quarter last year, the company earned $5.85 earnings per share. The firm’s revenue was up 11.7% on a year-over-year basis.

UTHR has been the subject of a number of other reports. UBS Group lowered their target price on United Therapeutics from $410.00 to $385.00 and set a “buy” rating for the company in a research note on Monday, June 30th. Morgan Stanley lowered their price objective on shares of United Therapeutics from $348.00 to $328.00 and set an “equal weight” rating for the company in a research report on Thursday, July 10th. Wall Street Zen downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 2nd. Bank of America decreased their price target on shares of United Therapeutics from $321.00 to $315.00 and set a “neutral” rating on the stock in a research note on Wednesday, June 11th. Finally, HC Wainwright set a $400.00 price target on shares of United Therapeutics and gave the company a “buy” rating in a report on Thursday. Four research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $379.69.

United Therapeutics Stock Performance

United Therapeutics stock opened at $294.28 on Friday. The firm has a market cap of $13.27 billion, a P/E ratio of 11.49, a P/E/G ratio of 5.97 and a beta of 0.57. The business’s fifty day moving average is $298.13 and its two-hundred day moving average is $313.59. United Therapeutics has a 52 week low of $266.98 and a 52 week high of $417.82.

Hedge Funds Weigh In On United Therapeutics

Institutional investors have recently modified their holdings of the stock. FMR LLC raised its position in shares of United Therapeutics by 36.5% in the 4th quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company’s stock valued at $519,170,000 after acquiring an additional 393,777 shares during the period. Vaughan Nelson Investment Management L.P. bought a new stake in United Therapeutics in the first quarter valued at approximately $101,354,000. Nuveen LLC acquired a new stake in United Therapeutics in the first quarter worth $83,533,000. Amundi raised its holdings in United Therapeutics by 198.8% in the first quarter. Amundi now owns 350,193 shares of the biotechnology company’s stock worth $107,635,000 after purchasing an additional 232,988 shares during the period. Finally, GAMMA Investing LLC boosted its position in shares of United Therapeutics by 29,415.2% during the first quarter. GAMMA Investing LLC now owns 221,954 shares of the biotechnology company’s stock worth $68,422,000 after purchasing an additional 221,202 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at United Therapeutics

In other news, Director Nilda Mesa sold 645 shares of the stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total value of $187,043.55. Following the transaction, the director owned 4,883 shares of the company’s stock, valued at $1,416,021.17. This represents a 11.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Richard Giltner sold 3,036 shares of the firm’s stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $289.60, for a total value of $879,225.60. Following the completion of the transaction, the director owned 19,384 shares in the company, valued at $5,613,606.40. This represents a 13.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 70,681 shares of company stock worth $21,318,359 over the last quarter. 10.30% of the stock is currently owned by insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.